Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIKTAM: Buparlisib and Tamoxifen in HR+/HER2- Advanced Breast Cancer
NCT02404844Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Dec 2014
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in breast cancer, sponsored by Universitätsmedizin Essen. Primary endpoint: Progression Free Survival rate at 6 months. Started Dec 2014; status: completed.
02
Drugs
buparlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02404844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404844.